Advances in Radiotherapy for Tumors Involving the Mediastinum

Thoracic Surgery Clinics

Volumn 19, Issue 1, 2009, Pages 133-141

  Choe, Kevin S ^a   Salama, Joseph K ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Innovations; Mediastinum; Radiation therapy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED RADIOTHERAPY; ESOPHAGITIS; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDIASTINUM TUMOR; MESOTHELIOMA; MYELITIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THYMOMA; TREATMENT PLANNING;

CARBON RADIOISOTOPES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LYMPHOMA; MEDIASTINAL NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SMALL CELL LUNG CARCINOMA; THYMOMA; THYMUS NEOPLASMS;

EID: 58149328486     PISSN: 15474127     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2008.09.010     Document Type: Review

References (60)

1. Azarow K.S., Pearl R.H., Zurcher R., et al. Primary mediastinal masses. A comparison of adult and pediatric populations. J Thorac Cardiovasc Surg 106 1 (1993) 67-72
2. Davis Jr. R.D., Oldham Jr. H.N., and Sabiston Jr. D.C. Primary cysts and neoplasms of the mediastinum: recent changes in clinical presentation, methods of diagnosis, management, and results. Ann Thorac Surg 44 3 (1987) 229-237
3. Lewis J.E., Wick M.R., Scheithauer B.W., et al. Thymoma. A clinicopathologic review. Cancer 60 11 (1987) 2727-2743
4. Curran Jr. W.J., Kornstein M.J., Brooks J.J., et al. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 6 11 (1988) 1722-1727
5. Arakawa A., Yasunaga T., Saitoh Y., et al. Radiation therapy of invasive thymoma. Int J Radiat Oncol Biol Phys 18 3 (1990) 529-534
6. Ichinose Y., Ohta M., Yano T., et al. Treatment of invasive thymoma with pleural dissemination. J Surg Oncol 54 3 (1993) 180-183
7. Wright C.D., Choi N.C., Wain J.C., et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 85 2 (2008) 385-389
8. Priola A.M., Priola S.M., Cardinale L., et al. The anterior mediastinum: diseases. Radiol Med (Torino) 111 3 (2006) 312-342
9. Aleman B.M., Raemaekers J.M., Tirelli U., et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 24 (2003) 2396-2406
10. Addis B.J., and Isaacson P.G. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology 10 4 (1986) 379-390
11. Trump D.L., and Mann R.B. Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement. Cancer 50 2 (1982) 277-282
12. Waldron Jr. J.A., Dohring E.J., and Farber L.R. Primary large cell lymphomas of the mediastinum: an analysis of 20 cases. Semin Diagn Pathol 2 4 (1985) 281-295
13. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 1 (1998) 21-26
14. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 6 (1997) 1710-1717
15. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III nonsmall cell lung cancer. N Engl J Med 323 14 (1990) 940-945
16. Sause W., Kolesar P., Taylor S.I., et al. Final results of phase III trial in regionally advanced unresectable nonsmall cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117 2 (2000) 358-364
17. Curran W., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proceedings of American Society of Clinical Oncology 22 (2003) 621 [abstract]
18. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III nonsmall cell lung cancer. J Clin Oncol 17 9 (1999) 2692-2699
19. Zatloukal P.V., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with vinorelbine plus cisplatin in locally advanced nonsmall cell lung cancer. A randomized phase II study. Proceedings of American Society of Clinical Oncology 21 (2002) 290A [Abstract]
20. Albain K.S., Swann R.S., Rusch V.R., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) nonsmall cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 23 16S (2005) 7014
21. Shaikh A.Y., Haraf D.J., Salama J.K., et al. Chemotherapy and high-dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol 30 3 (2007) 258-263
22. Socinski M.A., Blackstock A.W., Bogart J.A., et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III nonsmall cell lung cancer: CALGB 30105. J Clin Oncol 26 15 (2008) 2457-2463
23. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in nonsmall cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352 9124 (1998) 257-263
24. Burdett S., and Stewart L. Postoperative radiotherapy in nonsmall cell lung cancer: update of an individual patient data meta-analysis. Lung Cancer 47 1 (2005) 81-83
25. Bekelman J.E., Rosenzweig K.E., Bach P.B., et al. Trends in the use of postoperative radiotherapy for resected nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 66 2 (2006) 492-499
26. Lally B.E., Zelterman D., Colasanto J.M., et al. Postoperative radiotherapy for stage II or III nonsmall cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 24 19 (2006) 2998-3006
27. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 9 (2006) 719-727
28. Douillard J.Y., Rosell R., De Lena M., et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA nonsmall cell lung cancer treated with adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys 72 3 (2008) 695-701
29. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343 17 (2000) 1217-1222
30. Bradley J.D., Paulus R., Graham M.V., et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA nonsmall cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 23 15 (2005) 3480-3487
31. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327 23 (1992) 1618-1624
32. Warde P., and Payne D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 6 (1992) 890-895
33. Turrisi III A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 4 (1999) 265-271
34. Kalender W.A., and Polacin A. Physical performance characteristics of spiral CT scanning. Med Phys 18 5 (1991) 910-915
35. Klingenbeck-Regn K., Schaller S., Flohr T., et al. Subsecond multislice computed tomography: basics and applications. Eur J Radiol 31 2 (1999) 110-124
36. Seppenwoolde Y., Lebesque J.V., de Jaeger K., et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 55 3 (2003) 724-735
37. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for nonsmall cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 2 (1999) 323-329
38. Bradley J., and Movsas B. Radiation esophagitis: predictive factors and preventive strategies. Semin Radiat Oncol 14 4 (2004) 280-286
39. Langen K.M., and Jones D.T. Organ motion and its management. Int J Radiat Oncol Biol Phys 50 1 (2001) 265-278
40. Sher D.J., Wolfgang J.A., Niemierko A., et al. Quantification of mediastinal and hilar lymph node movement using four-dimensional computed tomography scan: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 69 5 (2007) 1402-1408
41. Hanley J., Debois M.M., Mah D., et al. Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat Oncol Biol Phys 45 3 (1999) 603-611
42. Wong J.W., Sharpe M.B., Jaffray D.A., et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys 44 4 (1999) 911-919
43. Giraud P., Yorke E., Ford E.C., et al. Reduction of organ motion in lung tumors with respiratory gating. Lung Cancer 51 1 (2006) 41-51
44. Yorke E., Rosenzweig K.E., Wagman R., et al. Interfractional anatomic variation in patients treated with respiration-gated radiotherapy. J Appl Clin Med Phys 6 2 (2005) 19-32 Spring
45. Socinski M.A., Rosenman J.G., Halle J., et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 92 5 (2001) 1213-1223
46. Grills I.S., Yan D., Martinez A.A., et al. Potential for reduced toxicity and dose escalation in the treatment of inoperable nonsmall cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 57 3 (2003) 875-890
47. Murshed H., Liu H.H., Liao Z., et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 58 4 (2004) 1258-1267
48. Xiao Y., Werner-Wasik M., Michalski D., et al. Comparison of three IMRT inverse planning techniques that allow for partial esophagus sparing in patients receiving thoracic radiation therapy for lung cancer. Med Dosim 29 3 (2004) 210-216 Fall
49. Sura S., Gupta V., Yorke E., et al. Intensity-modulated radiation therapy (IMRT) for inoperable nonsmall cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87 1 (2008) 17-23
50. Bortfeld T., Jokivarsi K., Goitein M., et al. Effects of intrafraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol 47 13 (2002) 2203-2220
51. Chui C.S., Yorke E., and Hong L. The effects of intrafraction organ motion on the delivery of intensity-modulated field with a multileaf collimator. Med Phys 30 7 (2003) 1736-1746
52. Rice D.C., Smythe W.R., Liao Z., et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69 2 (2007) 350-357
53. Chang J.Y., Zhang X., Wang X., et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 65 4 (2006) 1087-1096
54. Hata M., Tokuuye K., Kagei K., et al. Hypofractionated high-dose proton beam therapy for stage I nonsmall cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys 68 3 (2007) 786-793
55. Bush D.A., Slater J.D., Shin B.B., et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 126 4 (2004) 1198-1203
56. Miyamoto T., Baba M., Yamamoto N., et al. Curative treatment of stage I nonsmall cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 67 3 (2007) 750-758
57. Miyamoto T., Baba M., Sugane T., et al. Carbon ion radiotherapy for stage I nonsmall cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2 10 (2007) 916-926
58. Blomgren H., Lax I., Naslund I., et al. Stereotactic high dose-fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 34 6 (1995) 861-870
59. Timmerman R.D., Park C., and Kavanagh B.D. The North American experience with stereotactic body radiation therapy in nonsmall cell lung cancer. J Thorac Oncol 2 7 Suppl 3 (2007) S101-S112
60. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early stage lung cancer. J Clin Oncol 24 30 (2006) 4833-4839